menu
    • menu

    Company profile for Diagonal Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Diagonal Therapeutics is a trailblazing biotech firm revolutionizing the discovery and development of agonist antibodies. Leveraging our proprietary DIAGONAL platform, we integrate cutting-edge computational and experimental methods to overcome longstanding obstacles in agonist antibody drug discovery. Our burgeoning pipeline, crafted through the DIAGONAL platform, holds promise in delivering transformative treatments to patie...
    Diagonal Therapeutics is a trailblazing biotech firm revolutionizing the discovery and development of agonist antibodies. Leveraging our proprietary DIAGONAL platform, we integrate cutting-edge computational and experimental methods to overcome longstanding obstacles in agonist antibody drug discovery. Our burgeoning pipeline, crafted through the DIAGONAL platform, holds promise in delivering transformative treatments to patients, including therapies tailored for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Diagonal TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Floor 8, Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.diagonaltx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/diagonal-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Diagonal Therapeutics Secures $125M Series B
    Diagonal Therapeutics Secures $125M Series B

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215162/0/en/Diagonal-Therapeutics-Announces-Oversubscribed-125-Million-Series-B-Financing-to-Advance-Clinical-Development-of-Disease-Modifying-Clustering-Antibody-Pipeline.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    Diagonal Therapeutics To Share HHT, IMPACT, Study Insights At ASH
    Diagonal Therapeutics To Share HHT, IMPACT, Study Insights At ASH

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199709/0/en/Diagonal-Therapeutics-to-Present-Insights-from-HHT-IMPACT-a-Natural-History-Study-Initiated-in-Partnership-with-Cure-HHT-at-ASH-2025.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Diagonal Therapeutics Characterizes HHT Impact on Healthcare
    Diagonal Therapeutics Characterizes HHT Impact on Healthcare

    10 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/10/3113099/0/en/Diagonal-Therapeutics-Announces-Publication-of-Data-Characterizing-the-Healthcare-System-Cost-and-Impact-of-Hereditary-Hemorrhagic-Telangiectasia-HHT-in-the-American-Journal-of-Hem.html

    GLOBENEWSWIRE
    10 Jul 2025
    Share Share
    Diagonal Therapeutics Names John Lee as Chief Medical Officer
    Diagonal Therapeutics Names John Lee as Chief Medical Officer

    08 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/08/3111593/0/en/Diagonal-Therapeutics-Appoints-John-Lee-M-D-Ph-D-as-Chief-Medical-Officer.html

    GLOBENEWSWIRE
    08 Jul 2025
    Share Share
    Diagonal’s DIAG723 Antibody Gets ODD from U.S. FDA and EMA
    Diagonal’s DIAG723 Antibody Gets ODD from U.S. FDA and EMA

    18 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/18/3101304/0/en/Diagonal-s-First-in-Class-Clustering-Antibody-DIAG723-Receives-Orphan-Drug-Designation-ODD-from-U-S-FDA-and-an-ODD-Positive-Opinion-from-EMA-for-Treatment-of-Hereditary-Hemorrhagic.html

    GLOBENEWSWIRE
    18 Jun 2025
    Share Share
    Diagonal Therapeutics to Present Disease-Modifying Data at EHA
    Diagonal Therapeutics to Present Disease-Modifying Data at EHA

    12 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/12/3098057/0/en/Diagonal-Therapeutics-to-Present-New-Preclinical-Data-Demonstrating-Disease-Modifying-Potential-of-Receptor-Clustering-Antibody-Approach-in-HHT-at-EHA-2025-Congress.html

    GLOBENEWSWIRE
    12 Jun 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Diagonal Therapeutics Raises $125M for Antibody Pipeline Clinical Development

    Details:

    The Series B financing for DIAG723, an unconjugated antibody targeting ALK-1 receptor, will advance the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).


    Lead Product(s): DIAG723

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Antibody, Unconjugated

    Sponsor: Sanofi Ventures | Janus Henderson Investors | Track Capital

    Deal Size: $125.0 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing January 08, 2026

    blank

    01

    Diagonal Therapeutics

    U.S.A
    arrow
    Annual COG
    Not Confirmed

    Diagonal Therapeutics

    U.S.A
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : DIAG723

    Therapeutic Area : Genetic Disease

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Sanofi Ventures | Janus Henderson Investors | Track Capital

    Deal Size : $125.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Diagonal Therapeutics Raises $125M for Antibody Pipeline Clinical Development

    Details : The Series B financing for DIAG723, an unconjugated antibody targeting ALK-1 receptor, will advance the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    January 08, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Diagonal’s DIAG723 Gets Orphan Drug Status From FDA, EMA For HHT

    Details:

    ‍DIAG723 is a bispecific antibody designed to address HHT and PAH, in which dysregulated ALK1 signaling in endothelial cells drives the formation of arteriovenous malformations.


    Lead Product(s): DIAG723

    Therapeutic Area: Genetic Disease Brand Name: DIAG723

    Study Phase: IND EnablingProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 18, 2025

    blank

    02

    Diagonal Therapeutics

    U.S.A
    arrow
    Annual COG
    Not Confirmed

    Diagonal Therapeutics

    U.S.A
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : DIAG723

    Therapeutic Area : Genetic Disease

    Highest Development Status : IND Enabling

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Diagonal’s DIAG723 Gets Orphan Drug Status From FDA, EMA For HHT

    Details : ‍DIAG723 is a bispecific antibody designed to address HHT and PAH, in which dysregulated ALK1 signaling in endothelial cells drives the formation of arteriovenous malformations.

    Product Name : DIAG723

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    June 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Diagonal Launches with $128 Million to Develop Agonist Antibodies for Diseases

    Details:

    The financing proceeds fund the clinical advancement of Diagonal's lead program, a TGF beta receptor agonist for the treatment of hereditary hemorrhagic telangiectasia.


    Lead Product(s): Undisclosed

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Undisclosed

    Sponsor: BVF Partners

    Deal Size: $128.0 million Upfront Cash: Undisclosed

    Deal Type: Financing April 03, 2024

    blank

    03

    Diagonal Therapeutics

    U.S.A
    arrow
    Annual COG
    Not Confirmed

    Diagonal Therapeutics

    U.S.A
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Genetic Disease

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : BVF Partners

    Deal Size : $128.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Diagonal Launches with $128 Million to Develop Agonist Antibodies for Diseases

    Details : The financing proceeds fund the clinical advancement of Diagonal's lead program, a TGF beta receptor agonist for the treatment of hereditary hemorrhagic telangiectasia.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    April 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search